| Aug 9 |
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
|
| Aug 9 |
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
|
| Aug 8 |
SpringWorks Q2 Earnings Beat, Ogsiveo Drives Revenues
|
| Aug 8 |
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
|
| Aug 5 |
Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know
|
| Aug 5 |
Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know
|
| Aug 5 |
Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?
|
| Aug 1 |
Fulcrum Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Jul 31 |
Fulcrum Therapeutics, Inc. (FULC) Q2 2024 Earnings Call Transcript
|
| Jul 31 |
Fulcrum Therapeutics GAAP EPS of $0.87 beats by $0.88, revenue of $80M beats by $38.89M
|
